Eagle Pharmaceuticals prices IPO at $15, the midpoint of the range


Shutterstock photo

Eagle Pharmaceuticals, which develops and sells enhanced injectable versions of expiring patented drugs, raised $50 million by offering 3.4 million shares at $15, the midpoint of the range of $14 to $16. Eagle Pharmaceuticals plans to list on the NASDAQ under the symbol EGRX. Eagle Pharmaceuticals initially filed confidentially on 10/21/2013. Piper Jaffray and William Blair acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com